3D Cell Culture Market is valued at USD 1.51 Billion in 2022 and expected to reach USD 4.56 Billion by 2029 with the a CAGR of 17.1% over the forecast period
3D cell culture technique generates normal cell morphology, proliferation, differentiation and migration. It offers an ideal environment for cell culture analytical studies, which involve assessment of multi-stage disease models with the help of 3D cellular modeling. It is a controlled simulated environment outside of a living organism, where cells are allowed to grow and migrate by interacting within their habitat.
3D cell culture cultivates levels of cell differentiation and tissue organization which is not possible in traditional 2D culture systems. It has properties like tissue divergence and cell cohesion properties. It is becoming more popular and have shown increased applications, especially in the novel drug discovery and other research and development.
This technique is utilized by researchers to fabricate physiologically similar cell culture stereotypes that aid drug discovery and development. Persistent need to refine efficiency in pharmaceutical research and development is also encouraging the use of 3D cell cultures.
The outbreak of COVID-19 has resulted in a surge of interest in cell culture as a platform for developing novel vaccines for the treatment of the disease. 3D cell culture market players have taken initiatives in this direction, with Captivate Bio launching its portfolio of cell culture tools to assist in the fight against COVID-19 and other emerging diseases in the United States in January 2021. This has had a noticeable effect on the growth of the market.
The increasing demand for personalized medicine, along with the rising demand for vaccines, biopharmaceuticals, and artificial organs, is fueling the growth of the market. Furthermore, technological advancements and the launch of products and consumables are also contributing to 3D cell culture market growth over the forecast period.
Some of the key players for global 3D cell culture market are
Scaffold-based technology held the largest market share in terms of revenue. This is largely due to its ability to replicate the native extracellular matrix, which enables the incorporation of sophisticated biochemical and mechanical signals. Additionally, the increasing demand for advancements in the field of hydrogels for the study of human and cellular physiology, as well as the launch of new products, is expected to further drive the growth of the 3D cell culture market in the coming years.
The research conducted by the Southern University of Science and Technology, China and Adocia, the Paris-based biopharmaceutical company, in January 2021 demonstrated the potential of 3D-printed hydrogel scaffolds for use in cell therapy of Type 1 diabetes. By overcoming the limitations of hydrogel-polymer-based scaffolds in terms of performance and functionality, the two research teams were able to develop highly stretchable hydrogels that can be used for this purpose.
The cancer segment holds the greatest share of the 3D cell culture market in terms of revenue. The development of anticancer therapies is being boosted by the use of spheroids as model systems. Furthermore, the utilization of 3-dimensional cellular models for the study of cancer biology in preclinical testing and screening is projected to augment revenue for this segment.
In January 2021, a scientific research study reported the development of polysaccharide hydrogel-based 3D printed tumor models. These models can be used for high throughput screening of anti-cancer drugs, as they efficiently imitate the tumor microenvironment and show appropriate biocompatibility, rheological characteristics, and printability. This development is expected to lead to an increased use of scaffold-based techniques for cancer.
The anticipated rise in applications of 3D cell culture platforms for regenerative medicine is expected to propel the segment growth. This was further exemplified in January 2020, when Histogen, Inc., a company engaged in the development of regenerative medicine, entered into a merger with Conatus Pharmaceuticals, Inc., which exhibits a robust pipeline of unique clinical candidates, including an extracellular matrix scaffold targeted toward the treatment of conditions associated with articular cartilage.
advantages of 3D cell cultures over 2D cell cultures for drug discovery and development. 3D cell cultures offer optimal oxygen and nutrient gradients, non-uniform exposure of cells within a spheroid to a drug, and realistic cell-to-cell interactions, making them more suitable for studying drug candidates. This has boosted the demand for 3D cell cultures, resulting in a higher revenue share for the biotechnology and pharmaceutical industries.
The urgent need for more rapid and accurate diagnostic services, as well as the advantages of 3D models over 2D models in providing detailed physiological information, are driving the growth of the hospitals and diagnostic centers segment. Furthermore, the presence of diagnostic centers, such as Kiyatec, which are actively involved in providing 3D models for advanced research, is expected to further boost the segment growth in the near future.
3D cell culture is becoming imperative in the healthcare sector due to its significant range of applications in cancer research, in vitro environment, and regenerative medicine. The necessary help from 3D cell culture to strengthen the understanding of tissue maturation and organization, organogenesis, and cell differentiation has increased its utility. It has also replaced animal prototypes in clinical testing and experiments, as these cells look similar to cells in vivo.
All these applications are anticipated to derive the growth of 3D cell culture market in the coming few years. Increase in adoption of 3D cell culture in diagnostic centers, hospitals, and pharmaceutical and biotech companies, and rise in demand of 3D cell culture in organ transplantation, tissue regeneration, and regenerative medicine are also propelling the growth in this market.
The 3D cell culture market is expected to grow at a rapid rate due to factors such as increasing R&D activities in drug discovery, rising prevalence of cancer, and increasing demand for personalized medicines. Additionally, the increasing number of collaborations between research institutes and biotechnology companies is also driving the market. Furthermore, with the development of advanced technology, such as 3D cell culture and microfluidics, the 3D cell culture market is likely to witness significant growth in the upcoming years.
The launch of Thermo Fisher Scientific's new Gibco Human Plasma-like Medium (HPLM) in March 2021 is expected to drive the growth of the 3D cell culture market. HPLM is one of the first types of cell culture medium that replicates the metabolic profile of human plasma, providing researchers with a realistic view of cell growth within the human body.
The launch of technologically advanced and innovative products, such as Nucleus Biologics' Krakatoa in February 2022, is expected to drive the growth of the market. Krakatoa is an innovative media maker that allows researchers to manufacture cell culture media at the point of use.
- In June 2022, Evonik debuted the cQrex portfolio, a range of cell culture ingredients designed to improve the efficacy and productivity of bioprocesses used to manufacture vaccines, monoclonal antibodies, therapeutic cells, and viral vectors.
- In February of 2022, CellulaREvolution was able to secure GBP 1.75 million in funding to expedite the introduction of its groundbreaking continuous cell culture technology.
|Historical data||2016 - 2021|
|Forecast Period||2022 - 2029|
|Market Size in 2022:||USD 1.51 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2029:||USD 4.56 Billion|
|Tables, Charts & Figures:||175|
3D Cell Culture Companies
|Thermo Fisher Scientific, Becton Dickinson and Company, Corning Incorporated, Sigma-Aldrich Corporation, 3D Biomatrix, 3D Biotek, Reinnervate, InSphero AG, Global Cell Solutions, Lonza Group, VWR International, Nano3D Biosciences, Tecan, Merck KGaA, PromoCell GmbH, Greiner Bio One International GmbH, Avantor Performance Materials, LLC, REPROCELL Inc., MIMETAS BV, and others.|
|Segments Covered||By Technology, By Application, By End-user|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|